» Articles » PMID: 17522068

Promoter Hypermethylation is Associated with Current Smoking, Age, Gender and Survival in Bladder Cancer

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2007 May 25
PMID 17522068
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Hypermethylation of tumor suppressor genes is central to the pathogenesis of human malignancy, yet this alteration's etiology remains unclear, and its clinical impact has not yet been studied using an approach that can yield directly generalizable results. Therefore, we sought to examine both of these issues in bladder cancer, seeking to understand the characteristics of epidemiologically well-defined patient tumors with differing levels of methylation silencing. We analyzed epigenetic silencing of 16 genes in a population-based incident case series of 331 bladder transitional cell carcinomas. We utilized a novel item response theory (IRT) model, to examine, in an unbiased fashion, the relationship of patient characteristics, carcinogen exposure history and tumor characteristics with the underlying propensity for gene hypermethylation. Age, male gender and current cigarette smoking were significantly positively associated with the methylation latent trait. Promoter hypermethylation as a latent trait significantly predicted both non-invasive/high-grade and invasive stage disease and was also significantly associated with survival, with each unit increase in the latent trait resulting in a 30% increase in the risk of death. This work, studying all stages and grades of incident bladder cancer, provides definitive evidence that carcinogen exposures play a critical role in selecting these alterations in tumorous clones and that epigenetic silencing is a strong and significant predictor of tumor stage and overall patient survival. Finally, our novel approach provides insight into the etiology of promoter hypermethylation, suggesting that selected, carcinogen-exposed individuals have a greater propensity for hypermethylation that is associated with more aggressive, fatal disease.

Citing Articles

Adenomatous Polyposis Coli (APC) Promoter Gene Methylation in Urine-Derived DNA: A Non-invasive Biomarker for Early Bladder Cancer Detection and Tumor Aggressiveness.

Aqerrout M, Mharrach I, Tadlaoui K, Laraqui A, Tagajdid M, Ennibi K Cureus. 2024; 16(10):e72055.

PMID: 39569232 PMC: 11578617. DOI: 10.7759/cureus.72055.


Urinary Bladder Carcinoma in Females: A Clinico-Pathological Assessment.

Gupta R, Khan S, Mahajan M, Sharma P, Mahajan A Cureus. 2023; 15(5):e39753.

PMID: 37398730 PMC: 10311036. DOI: 10.7759/cureus.39753.


UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of isoforms in lung cancer.

Lin S, Xu H, Qin L, Pang M, Wang Z, Gu M Acta Pharm Sin B. 2023; 13(5):2086-2106.

PMID: 37250150 PMC: 10213989. DOI: 10.1016/j.apsb.2023.02.015.


CpG Site-Specific Methylation-Modulated Divergent Expression of Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma.

Lin S, Xu H, Pang M, Zhou X, Pan Y, Zhang L Front Oncol. 2022; 12:831268.

PMID: 35480112 PMC: 9035874. DOI: 10.3389/fonc.2022.831268.


Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer.

Moorthy H, Laxman Prabhu G, Venugopal P Indian J Urol. 2020; 36(3):171-178.

PMID: 33082631 PMC: 7531383. DOI: 10.4103/iju.IJU_320_19.